The SARS-CoV-2 virus emerged in December 2019 and then spread rapidly worldwide, particularly to China, Japan, and South Korea. Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far. This article summarizes agents with potential efficacy against SARS-CoV-2.

The virus SARS-CoV-2 (formerly designated 2019nCoV) emerged in December 2019 and then spread rapidly worldwide, particularly to China, Japan, and South Korea. As of February 21, 2020, a total of 76,288 confirmed cases of coronavirus disease 2019 (COVID-19) and 2,345 deaths have been reported in mainland China (1). Scientists are endeavoring to find drugs to treat this disease. Research thus far has revealed more than 30 agents including Western medicines, natural products, and traditional Chinese medicines that may have potential efficacy against COVID-19. Some of these agents have been quickly tested in clinical studies and demonstrated preliminary efficacy against COVID-19. Antivirals including interferon α (IFN-α), lopinavir/ritonavir, chloroquine phosphate, ribavirin, and arbidol have been included in the latest version of the Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia issued by the National Health Commission (NHC) of the People’s Republic of China for tentative treatment of COVID-19 .

Journal of Pharmaceutical Sciences & Emerging Drugs - Subscription using online manuscript submission, review and tracking systems of SciTechnol for quality and quick review processing.Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process. Publishers can see what manuscripts are in the pipeline awaiting publication. Email is sent automatically to appropriate parties when significant events occur.

Submit manuscripts at https://www.scholarscentral.org/submissions/pharmaceutical-sciences-emerging-drugs.html or an e-mail attachment to the Editorial Office at editor.jpsed@peerjournal.org

Best Regards,
Editorial Assistant
Journal of Pharmaceutical Sciences & Emerging Drugs
E-mail: editor.jpsed@scitechnol.com
What’sapp No.: +1-579-679-8957